群体药代动力学作为一种检测患有行为障碍的痴呆患者中利培酮暴露量变异的方法。

Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances.

作者信息

Bies Robert R, Mulsant Benoit H, Rosen Jules, Huber Kimberly A, Wilson Nicole L, Kirshner Margaret A, Pollock Bruce G

机构信息

Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.

出版信息

Am J Geriatr Pharmacother. 2005 Jun;3(2):87-91. doi: 10.1016/j.amjopharm.2005.07.002.

DOI:10.1016/j.amjopharm.2005.07.002

PMID:16129385

Abstract

OBJECTIVE

This study was intended to compare the consistency of risperidone exposure in patients who have dementia and behavioral disturbances treated in a psychiatric hospital versus a community care setting.

METHODS

Population pharmacokinetic modeling was used to assess the consistency of risperidone exposure in Alzheimer's disease patients with agitation. The ratio of predicted to observed drug concentrations (Cpred/Cobs) derived from this model was used to compare exposure in the inpatient versus long-term/home care settings using both the mean and the variance of this term across groups.

RESULTS

The modeled Cpred/Cobs ratios had a much higher within-subject variance in the inpatients than in the community care patients (117.03% vs 72.35%; P < 0.001). The central tendencies of the Cpred/Cobs ratios across the 2 groups were not significantly different.

CONCLUSIONS

Exposure to risperidone was more variable in a psychiatric hospital than in a community care setting. Future research may help to identify the specific contributors to the increased variance observed in this pilot study.

摘要